Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
The atypical antipsychotic quetiapine induces hyperlipidemia by activating intestinal PXR signaling
Zhaojie Meng, Taesik Gwag, Yipeng Sui, Se-Hyung Park, Xiangping Zhou, Changcheng Zhou
Zhaojie Meng, Taesik Gwag, Yipeng Sui, Se-Hyung Park, Xiangping Zhou, Changcheng Zhou
View: Text | PDF
Research Article Endocrinology Metabolism

The atypical antipsychotic quetiapine induces hyperlipidemia by activating intestinal PXR signaling

  • Text
  • PDF
Abstract

Quetiapine, one of the most prescribed atypical antipsychotics, has been associated with hyperlipidemia and an increased risk for cardiovascular disease in patients, but the underlying mechanisms remain unknown. Here, we identified quetiapine as a potent and selective agonist for pregnane X receptor (PXR), a key nuclear receptor that regulates xenobiotic metabolism in the liver and intestine. Recent studies have indicated that PXR also plays an important role in lipid homeostasis. We generated potentially novel tissue-specific PXR-KO mice and demonstrated that quetiapine induced hyperlipidemia by activating intestinal PXR signaling. Quetiapine-mediated PXR activation stimulated the intestinal expression of cholesterol transporter Niemann-Pick C1-Like 1 (NPC1L1) and microsomal triglyceride transfer protein (MTP), leading to increased intestinal lipid absorption. While NPC1L1 is a known PXR target gene, we identified a DR-1–type PXR-response element in the MTP promoter and established MTP as a potentially novel transcriptional target of PXR. Quetiapine’s effects on PXR-mediated gene expression and cholesterol uptake were also confirmed in cultured murine enteroids and human intestinal cells. Our findings suggest a potential role of PXR in mediating adverse effects of quetiapine in humans and provide mechanistic insights for certain atypical antipsychotic-associated dyslipidemia.

Authors

Zhaojie Meng, Taesik Gwag, Yipeng Sui, Se-Hyung Park, Xiangping Zhou, Changcheng Zhou

×

Figure 2

Quetiapine binds to PXR and modulates PXR and coregulator interactions.

Options: View larger image (or click on image) Download as PowerPoint
Quetiapine binds to PXR and modulates PXR and coregulator interactions.
...
(A) Inhibition of FRET between fluorescein-labeled PXR ligand and recombinant GST-PXR by quetiapine or aripiprazole. Results are expressed as the signal from the fluorescein emission divided by the terbium signal to provide a TR-FRET emission ratio (n = 3). (B and C) HepG2 cells were transfected with a GAL4 reporter, VP16-hPXR vector, and expression vector for GAL4 DNA-binding domain or GAL4 DNA-binding domain linked to the receptor interaction domains of PXR coactivators (GAL4-SRC1 or GAL4-PBP) (B) or PXR corepressors (GAL4-SMRT or GAL4-NCoR) (C). Cells were treated with DMSO control, quetiapine, or rifampicin at the indicated concentrations for 24 hours. Data are shown as fold induction of normalized luciferase activity compared with DMSO control treatment (n = 3, 1-way ANOVA, *P < 0.05, **P < 0.01, and ***P < 0.001 compared with control group).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts